


What is claimed is:

1. A compound of formula (I)



including salts, solvates, and physiologically functional derivatives thereof, wherein

R^1 is $-(Q^1)_x-R^5$;

Q^1 is alkylene;

x is 0 or 1;

R^5 is H, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl;

R^2 is $-(Q^3)-(Q^4)-R^6$, or $-(Q^3)-CN$;

Q^3 is alkylene;

Q^4 is $-C(O)-$, $-C(S)-$, or $-C(NR^7)-$,

R^7 is H or alkyl;

R^6 is alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, or $-N(R^8)(R^9)$

R^8 and R^9 each independently are H, hydroxy, alkyl, alkenyl, alkynyl, $-(Q^5)_y$ -cycloalkyl,

$-N(R^{10})(R^{11})$, or R^8 and R^9 combine with the nitrogen atom to which they are attached to form an optionally substituted 4 to 8 membered ring that may contain additional heteroatoms and may contain one or more degrees of unsaturation;

Q^5 is alkylene;

y is 0 or 1;

R^{10} and R^{11} each independently are H or alkyl;

R^3 is $-CN$, $-NO_2$, or halogen; and

R^4 is $-CN$, $-NO_2$, halogen, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, aryl, aryloxy.

2. The compound of claim 1 wherein alkyl is C_1 - C_6 alkyl, alkenyl is C_1 - C_6 alkenyl, alkynyl is C_1 - C_6 alkynyl, haloalkyl is C_1 - C_6 haloalkyl, cycloalkyl is C_3 - C_6 cycloalkyl, alkylene is C_1 - C_6 alkylene, aryl is phenyl or naphthyl, alkoxy is C_1 - C_6 alkoxy, aryloxy is phenoxy or benzyloxy.
3. The compound of claim 2 wherein alkylene is C_1 - C_2 alkylene, haloalkyl is $-CF_3$, cycloalkyl is cyclopropyl.
4. The compound of claim 1 wherein alkylene is branched alkylene.
5. The compound of claim 4 wherein alkylene is $-CH(CH_3)-$ or $-CH(CH_2CH_3)-$.

6. The compound of claim 1 wherein R^2 is $-(Q^3)-CN$.
7. The compound of claim 6 wherein Q^3 is methylene.
8. The compound of claim 1 wherein R^3 is $-CN$.
9. The compound of claim 1 wherein R^4 is halogen, haloalkyl, $-CN$ or alkyl.
10. The compound of claim 9 wherein R^4 is haloalkyl.
11. The compound of claim 10 wherein R^4 is $-CF_3$.
12. The compound of claim 1 wherein Q^1 is methylene.
13. The compound of claim 1 wherein R^5 is $-CF_3$ or cyclopropyl.
14. The compound of claim 1 wherein Q^3 is methylene.
15. The compound of claim 1 wherein Q^4 is $-C(O)-$.
16. The compound of claim 1 wherein R^6 is $-N(R^8)(R^9)$, where R^8 and R^9 each independently are H or C_1-C_6 alkyl.
17. The compound of claim 1 wherein R^3 is $-CN$, R^4 is $-CF_3$, Q^1 is methylene, R^5 is $-CF_3$, Q^3 is methylene, Q^4 is $-C(O)-$, R^6 is $-N(R^8)(R^9)$, and R^8 and R^9 each are H.
18. A compound selected from:
 - 1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(cyclopropylmethyl)glycinate;
 - N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(cyclopropylmethyl)glycine;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)-*N*¹-methylglycinamide;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)glycinamide;
 - 1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-methylglycinate;
 - 1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-ethylglycinate;
 - N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-ethylglycine;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-ethylglycinamide;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-ethyl-*N*¹-propylglycinamide;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-(cyclopropylmethyl)-*N*²-ethylglycinamide;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-ethyl-*N*¹,*N*¹-dipropylglycinamide;
 - 1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)glycinate;
 - N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)glycine;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(2,2,2-trifluoroethyl)glycinamide;
 - methyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)glycinate;
 - 1-methylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)glycinate;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-methyl-*N*²-(2,2,2-trifluoroethyl)glycinamide;
 - N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-ethyl-*N*²-(2,2,2-trifluoroethyl)glycinamide;

*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-cyclohexyl-*N*²-(2,2,2-trifluoroethyl)glycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹,*N*¹-dimethyl-*N*²-(2,2,2-trifluoroethyl)glycinamide;
2-[4-cyano(2,2,2-trifluoroethyl)-3-(trifluoromethyl)anilino]-*N*-methylacetohydrazide;
2-[4-cyano(2,2,2-trifluoroethyl)-3-(trifluoromethyl)anilino]-*N*¹,*N*¹-dimethylacetohydrazide;
methyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)alaninate;
N-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2,2-trifluoroethyl)alanine;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(2,2,2-trifluoroethyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-methyl-*N*²-(2,2,2-trifluoroethyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-ethyl-*N*²-(2,2,2-trifluoroethyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹,*N*¹-dimethyl-*N*²-(2,2,2-trifluoroethyl)alaninamide;
1,1-dimethylethyl 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]butanoate;
2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]butanoic acid;
2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]butanamide;
2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-*N*-methylbutanamide;
2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-*N*-ethylbutanamide;
2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-*N*,*N*-dimethylbutanamide;
1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-propylglycinate;
N-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-propylglycine;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-propylglycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹,*N*²-dipropylglycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-(cyclopropylmethyl)-*N*²-propylglycinamide;
1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-2-propen-1-ylglycinate;
methyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2-fluoroethyl)glycinate;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(2-fluoroethyl)glycinamide;
1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2-methylpropyl)glycinate;
N-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-isobutylglycine;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-isobutylglycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-isobutyl-*N*¹-methylglycinamide;

*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)-*N*¹-ethylglycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹,*N*²-bis(cyclopropylmethyl)glycinamide;
1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-
(cyclopropylmethyl)alaninate;
N-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(cyclopropylmethyl)alanine;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)-*N*¹-methylanalinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)-*N*¹-ethylalaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(cyclopropylmethyl)-*N*¹,*N*¹-
dimethylalaninamide;
4-[(cyanomethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile;
4-[(1-cyanoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile;
methyl 3-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-2-
methylpropanoate;
4-[(2-cyanopropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile;
N-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(2,2-dimethylpropyl)glycine;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(2,2-dimethylpropyl)glycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(2,2,2-trifluoro-1-methylethyl)glycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-[1-(trifluoromethyl)propyl]glycinamide;
1,1-dimethylethyl *N*-[4-cyano-3-(trifluoromethyl)phenyl]-*N*-(3,3,3-
trifluoropropyl)glycinate;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(3,3,3-trifluoropropyl)glycinamide;
4-[(cyanomethyl)(3,3,3-trifluoropropyl)amino]-2-(trifluoromethyl)benzonitrile;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(3,3,3-trifluoropropyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-methyl-*N*²-(3,3,3-
trifluoropropyl)alaninamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(1,1-dimethylethyl)glycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*²-(1-methylethyl)glycinamide;
*N*²-[4-cyano-3-(trifluoromethyl)phenyl]-*N*¹-methyl-*N*²-(1-methylethyl)glycinamide;
4-[(cyanomethyl)(methyl)amino]-2-(trifluoromethyl)benzonitrile;
4-[(2-cyanoethyl)(methyl)amino]-2-(trifluoromethyl)benzonitrile;
1,1-dimethylethyl *N*-(3-chloro-4-cyanophenyl)-*N*-(2,2,2-trifluoroethyl)glycinate;
N-(3-chloro-4-cyanophenyl)-*N*-(2,2,2-trifluoroethyl)glycine;
*N*²-(3-chloro-4-cyanophenyl)-*N*²-(2,2,2-trifluoroethyl)glycinamide;
*N*²-(3-chloro-4-cyanophenyl)-*N*¹-methyl-*N*²-(2,2,2-trifluoroethyl)glycinamide;

N²-(3-chloro-4-cyanophenyl)-N¹-ethyl-N²-(2,2,2-trifluoroethyl)glycinamide;
1,1-dimethylethyl N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)alaninate;
N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)alanine;
N²-(3-chloro-4-cyanophenyl)-N²-(2,2,2-trifluoroethyl)alaninamide;
N²-(3-chloro-4-cyanophenyl)-N¹-methyl-N²-(2,2,2-trifluoroethyl)alaninamide;
N²-(3-chloro-4-cyanophenyl)-N¹-ethyl-N²-(2,2,2-trifluoroethyl)alaninamide;
1,1-dimethylethyl 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]butanoate;
2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]butanamide;
2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methylbutanamide;
2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethylbutanamide;
1,1-dimethylethyl N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)glycinate;
N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)glycine;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)glycinamide;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)-N¹-methylglycinamide;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)-N¹-ethylglycinamide;
2-chloro-4-[(cyanomethyl)(cyclopropylmethyl)amino]benzonitrile;
1,1-dimethylethyl N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)alaninate;
N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)alanine;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)alaninamide;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)-N¹-methylalaninamide;
N²-(3-chloro-4-cyanophenyl)-N²-(cyclopropylmethyl)-N¹-ethylalaninamide;
1,1-dimethylethyl 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]butanoate;
2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]butanoic acid;
2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]butanamide;
2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-methylbutanamide;
2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-ethylbutanamide;
methyl N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)glycinate;
1,1-dimethylethyl N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)glycinate;
N²-(3,4-dicyanophenyl)-N²-(2,2,2-trifluoroethyl)glycinamide;
N²-(3,4-dicyanophenyl)-N¹-methyl-N²-(2,2,2-trifluoroethyl)glycinamide;
N²-(3,4-dicyanophenyl)-N¹-ethyl-N²-(2,2,2-trifluoroethyl)glycinamide;
1,1-dimethylethyl N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)alaninate;
N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)alanine;
N²-(3,4-dicyanophenyl)-N²-(2,2,2-trifluoroethyl)alaninamide;
N²-(3,4-dicyanophenyl)-N¹-methyl-N²-(2,2,2-trifluoroethyl)alaninamide;

N^2 -(3,4-dicyanophenyl)- N^1 -ethyl- N^2 -(2,2,2-trifluoroethyl)alaninamide;
 1,1-dimethylethyl 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]butanoate;
 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]butanoic acid;
 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]butanamide;
 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methylbutanamide;
 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethylbutanamide;
 1,1-dimethylethyl N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)glycinate;
 N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)glycine;
 N^2 -(cyclopropylmethyl)- N^2 -(3,4-dicyanophenyl)glycinamide;
 N^2 -(cyclopropylmethyl)- N^2 -(3,4-dicyanophenyl)- N^1 -methylglycinamide;
 N^2 -(cyclopropylmethyl)- N^2 -(3,4-dicyanophenyl)- N^1 -ethylglycinamide;
 4-[(cyanomethyl)(cyclopropylmethyl)amino]-1,2-benzenedicarbonitrile;
 1,1-dimethylethyl N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)alaninate;
 N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)alanine;
 N^2 -(cyclopropylmethyl)- N^2 -(3,4-dicyanophenyl)- N^1 -methylalaninamide;
 N^2 -(cyclopropylmethyl)- N^2 -(3,4-dicyanophenyl)- N^1 -ethylalaninamide;
 1,1-dimethylethyl 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]butanoate;
 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]butanoic acid;
 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]butanamide;
 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-methylbutanamide;
 and 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-ethylbutanamide.

19. A compound as claimed in claims 1-18 substantially as hereinbefore defined with reference to any one of the Examples.
20. A pharmaceutical composition comprising a compound according to claims 1 to 18, and a pharmaceutically acceptable carrier.
21. A compound according to claims 1 to 18 for use as an active therapeutic substance.
22. A compound according to claims 1 to 18 for use in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation.
23. A compound according to claims 1 to 18 for use in the treatment or prophylaxis of osteoporosis, muscle wasting, frailty, cardiovascular disease, breast cancer, uterine cancer, prostate hyperplasia, prostate cancer, dyslipidemia, menopausal vasomotor conditions, urinary incontinence, arteriosclerosis, libido enhancement, depression, uterine fibroid disease, aortic smooth muscle cell proliferation, endometriosis, or ADAM.

24. Use of a compound according to claims 1 to 18 in the manufacture of a medicament for use in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation.
25. Use of a compound according to any one of claims 1 to 18 in the manufacture of a medicament for use in the treatment or prophylaxis of osteoporosis, muscle wasting, frailty, cardiovascular disease, breast cancer, uterine cancer, prostatic hyperplasia, prostate cancer, dyslipidemia, menopausal vasomotor conditions, urinary incontinence, arteriosclerosis, libido enhancement, depression, uterine fibroid disease, aortic smooth muscle cell proliferation, endometriosis, or ADAM.
26. A method for the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation comprising the administration of a compound according to any one of claims 1 to 18.
27. A method for the treatment or prophylaxis of osteoporosis, muscle wasting, frailty, cardiovascular disease, breast cancer, uterine cancer, prostatic hyperplasia, prostate cancer, dyslipidemia, menopausal vasomotor conditions, urinary incontinence, arteriosclerosis, libido enhancement, depression, uterine fibroid disease, aortic smooth muscle cell proliferation, endometriosis, or ADAM comprising the administration of a compound according to any one of claims 1 to 18.